by Claire | Oct 23, 2022 | Uncategorized
DIADEM PRESENTS DATA AT AD/PD™ 2022 INTERNATIONAL CONFERENCE DEMONSTRATING ITS NEW ALZOSURE® CONFIRM BLOOD TEST HAS THE POTENTIAL TO ACCURATELY DIAGNOSE ALZHEIMER’S DISEASE —Have Identified Specific Post Translational Modifications of a Conformational Variant of p53...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES PUBLICATION OF PEER-REVIEWED ARTICLE DESCRIBING HOW POST-TRANSLATIONAL MODIFICATIONS OF P53 VARIANTS MAY CONTRIBUTE TO DEVELOPMENT OF ALZHEIMER’S DISEASE —Post-Translational Modifications of Conformational Variants of p53 Appear to Impact Pathogenesis...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES PUBLICATION OF PEER-REVIEWED ARTICLE DESCRIBING HOW POST-TRANSLATIONAL MODIFICATIONS OF P53 VARIANTS MAY CONTRIBUTE TO DEVELOPMENT OF ALZHEIMER’S DISEASE —Includes Multiple Studies Demonstrating that Post-Translational Modifications of Conformational...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM ANNOUNCES PUBLICATION OF CLINICAL STUDY CONFIRMING ITS ALZOSURE® PREDICT BLOOD TEST CAN ACCURATELY PREDICT PROGRESSION TO ALZHEIMER’S DISEASE SIX YEARS BEFORE DIAGNOSIS —AlzoSure® Predict Uses a Simple Blood Draw to Identify with High Accuracy Whether or Not...
by Claire | Oct 23, 2022 | Uncategorized
DIADEM PARTNERS WITH DEMENTIAS PLATFORM UK TO ADVANCE DIAGNOSIS AND TREATMENT OF ALZHEIMER’S DISEASE —Joins Public Private Partnership Building Integrated, Collaborative Initiatives to Better Understand, Diagnose and Treat Alzheimer’s Disease and Other Dementias—...
